These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 2968760

  • 1. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM.
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V, al-Abadi H, Nagel R.
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [Abstract] [Full Text] [Related]

  • 4. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M, Schröder FH, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R, Smith PH, Suciu S.
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
    Pavone-Macaluso M, Ingargiola GB, de Voogt H, Viggiano G, Barasolo E, Lardennois B, De Pauw M, Sylvester R.
    Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
    [No Abstract] [Full Text] [Related]

  • 7. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW, Uitterlinden P, de Jong FH.
    Cancer Res; 1988 Nov 01; 48(21):6063-8. PubMed ID: 2844399
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
    Pavone-Macaluso M, Martínez-Piñeiro JA, de Voogt H, Lardennois B, Nasta A, Zolfanelli R, Barasolo E, De Pauw M, Suciu S, Sulvester R.
    Arch Esp Urol; 1982 Nov 01; 35(5):304-11. PubMed ID: 6217788
    [No Abstract] [Full Text] [Related]

  • 9. [Orchiectomy and buserelin in combination with flutamide: comparative results in metastatic prostatic carcinoma].
    Mora MJ, Extramiana J, Paniagua P, González P, Mañas A, Pérez MJ, Navarro J, Arrizabalaga M.
    Actas Urol Esp; 1991 Nov 01; 15(6):548-52. PubMed ID: 1792994
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
    Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R.
    Eur Urol; 1995 Nov 01; 28(4):273-83. PubMed ID: 8575493
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ, Pavone-Macaluso M, Smith PH, de Pauw M, Suciu S.
    Prog Clin Biol Res; 1988 Nov 01; 260():111-7. PubMed ID: 2966403
    [No Abstract] [Full Text] [Related]

  • 15. Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate.
    Robinson MR.
    Prog Clin Biol Res; 1987 Nov 01; 243A():383-90. PubMed ID: 2958863
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Therapy of prostatic cancer with cyproterone acetate].
    Maier U.
    Wien Klin Wochenschr; 1988 Jan 08; 100(1):16-9. PubMed ID: 2964127
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial.
    Boel K, Van Poppel H, Goethuys H, Derluyn J, Vandenbroucke F, Popelier G, Casselman J, Billiet I, Vanuytsel L, Paridaens R, Baert L.
    Anticancer Res; 1999 Jan 08; 19(3B):2157-61. PubMed ID: 10472324
    [Abstract] [Full Text] [Related]

  • 20. EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
    Robinson MR.
    Prog Clin Biol Res; 1988 Jan 08; 260():101-10. PubMed ID: 2966402
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.